Earlier this week, the Trump administration unveiled a new drug pricing initiative, widely referred to as “TrumpRx.”
While the headlines surrounding TrumpRx focus on political theater, the reality is more complex—and the ripple effects will impact pharmacies, plan sponsors, and Pharmacy Benefit Managers (PBMs) in very different ways.
Read more about the administration’s actions towards drug pricing thus far and what TrumpRx truly entails for each stakeholder in the drug pricing ecosystem.
Author(s):
Dae Y. Lee, Shareholder
Email: dae.lee@bipc.com
Natalie C. Oehlers, Associate
Email: natalie.oehlers@bipc.com